Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8.
J Affect Disord. 2013 Sep 25;150(3):707-19. doi: 10.1016/j.jad.2013.05.042. Epub 2013 Jun 12.
Depressed and anxious patients often combine complementary and alternative medicine (CAM) therapies with conventional pharmacotherapy to self-treat symptoms. The benefits and risks of such combination strategies have not been fully evaluated. This paper evaluates the risk-benefit profile of CAM augmentation to antidepressants in affective conditions.
PubMed was searched for all available clinical reports published in English up to December 2012. Data were evaluated based on graded levels of evidence for efficacy and safety.
Generally, the evidence base is significantly larger for depression than for anxiety disorder. In unipolar depression, there is Level 2 evidence for adjunctive sleep deprivation (SD) and Free and Easy Wanderer Plus (FEWP), and Level 3 for exercise, yoga, light therapy (LT), omega-3 fatty acids, S-adenosylmethionine and tryptophan. In bipolar depression, there is Level 1 evidence for adjunctive omega-3s, Level 2 for SD, and Level 3 for LT and FEWP. In anxiety conditions, exercise augmentation has Level 3 support in generalized anxiety disorder and panic disorder. Though mostly well-tolerated, these therapies can only be recommended as third-line interventions due to the quality of available evidence.
Overall, the literature is limited. Studies often had methodological weaknesses, with little information on long-term use and on potential drug-CAM interactions. Many CAM studies were not published in English.
While several CAM therapies show some evidence of benefit as augmentation in depressive disorders, such evidence is largely lacking in anxiety disorders. The general dearth of adequate safety and tolerability data encourages caution in clinical use.
抑郁和焦虑患者常将补充和替代医学(CAM)疗法与传统药物疗法相结合,以自我治疗症状。这种联合治疗策略的益处和风险尚未得到充分评估。本文评估了在情感障碍中,CAM 对抗抑郁药的增效作用的风险-效益比。
检索了截至 2012 年 12 月在英文期刊上发表的所有关于 CAM 增效抗抑郁药的临床报告。根据疗效和安全性的分级证据水平评估数据。
一般来说,与焦虑障碍相比,抑郁症的证据基础明显更大。在单相抑郁中,有辅助睡眠剥夺(SD)和 Free and Easy Wanderer Plus(FEWP)的 2 级证据,以及运动、瑜伽、光照疗法(LT)、ω-3 脂肪酸、S-腺苷甲硫氨酸和色氨酸的 3 级证据。在双相抑郁中,有辅助ω-3 的 1 级证据,SD 的 2 级证据,LT 和 FEWP 的 3 级证据。在焦虑症中,运动增效在广泛性焦虑症和惊恐障碍中有 3 级证据支持。尽管这些疗法通常耐受性良好,但由于现有证据的质量,只能将其推荐为三线干预措施。
总体而言,文献有限。研究往往存在方法学上的弱点,关于长期使用和潜在药物-CAM 相互作用的信息很少。许多 CAM 研究并未以英文发表。
虽然一些 CAM 疗法在治疗抑郁症方面显示出一定的增效作用,但在焦虑症方面,这种证据则相对缺乏。由于缺乏足够的安全性和耐受性数据,鼓励在临床使用中谨慎行事。